RubenAMesaMDFACP

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

President, Levine Cancer Institute & Enterprise Cancer Service Line Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center Enterprise Senior Vice President, Atrium Health Vice Dean for Cancer Programs, Wake Forest University School of Medicine Professor of Medicine, Wake Forest University School of Medicine

Join to view full profile

Dr. Mesa is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mesa's full profile

Already have an account?

Office
1021 Morehead Medical Dr
Ste A
Charlotte, NC 28204
Phone+1 980-442-2000

Summary

Dr. Ruben Mesa is a hematologist, and leads cancer efforts for Atrium Health as President of Levine Cancer Institute and Executive Director of Atrium Health Wake Forest Baptist Comprehensive Cancer Center. He specializes in myeloproliferative neoplasms, drug development and health equity research

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1998 - 2002
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1995 - 1998
Mayo Clinic College of MedicineClass of 1995

Certifications & Licensure

TX State Medical License 2017 - 2026
AZ State Medical License 2009 - 2025
NC State Medical License 2023 - 2025
MN State Medical License 1996 - 2013
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2013-2014
Top Doctors:Arizona State Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2012-2013
Fellow (FACP) American College of Physicians, 2007
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia Start of enrollment: 2002 Aug 01
Completed
Phase 2
Azacitidine in Treating Patients With Myelofibrosis Start of enrollment: 2006 Aug 01
Terminated
Phase 2
Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders Start of enrollment: 2005 Sep 01
Completed
Early Phase 1
Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia Start of enrollment: 2004 Oct 01
Completed
Phase 2
Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura Start of enrollment: 2007 Jan 01
Completed
Early Phase 1
Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis Start of enrollment: 2008 Mar 01
Terminated
Phase 2
Correlative Biomarker Study in Patients With Myeloproliferative Disorders Start of enrollment: 2007 Apr 01
Completed
CC-4047 in Treating Patients With Myelofibrosis Start of enrollment: 2008 May 01
Completed
Phase 1, Phase 2
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis Start of enrollment: 2008 Aug 01
Completed
Phase 1, Phase 2
Azacitidine and Lenalidomide for Acute Myeloid Leukemia Start of enrollment: 2010 Apr 01
Completed
Phase 1, Phase 2
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Start of enrollment: 2011 Sep 01
Completed
Phase 2
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Start of enrollment: 2011 Sep 01
Completed
Phase 3
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF Start of enrollment: 2011 Jun 01
Completed
Phase 1, Phase 2
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis Start of enrollment: 2013 Oct 01
Completed
Phase 2
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML Start of enrollment: 2014 Feb 01
Completed
Phase 1, Phase 2
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea Start of enrollment: 2015 Jul 01
Active, not recruiting
Phase 1
MPN-RC 118 AVID200 in Myelofibrosis Start of enrollment: 2019 Feb 15
Completed
Phase 1
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation Start of enrollment: 2021 Jan 14
Completed
Phase 2
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance Start of enrollment: 2020 Aug 25
Active, not recruiting
Phase 3
Calm for Cancer Patients Receiving Chemotherapy Start of enrollment: 2022 Feb 01
Withdrawn
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Myelofibrosis symptom assessment form total symptom score version 4.0: measurement properties from the MOMENTUM phase 3 study.
Christina Daskalopoulou, Boris Gorsh, Gerasimos Dumi, Samineh Deheshi, Chad Gwaltney
Quality of Life Research. 2024-11-25
Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm.
Anthony M Hunter, Mrinal M Patnaik, Raphael Itzykson, Ruben Mesa, Chatchada Karanes
Blood. 2024-11-07
1 citations
Polycythemia vera: past, present and future.
Ami B Patel, Lucia Masarova, Ruben A Mesa, Gabriela Hobbs, Naveen Pemmaraju
Leukemia & Lymphoma. 2024-11-01

Abstracts/Posters

Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolit...
Ruben A Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Standardized Equation Model of Quality of Life in Myeloproliferative Neoplasms
Ruben A Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis
Ruben A Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermedi...
Ruben A Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database
Ruben A. Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Set...
Ruben A. Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Patient-Reported Outcomes (PRO) Data from Patients (Pts) with Essential Thrombocythemia (ET) Enrolled in the MOST Study
Ruben A. Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia
Ruben A Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

SOHO 2020: Bringing 'MPN Awareness' to Hematology Community
Mayo School of Continuous Professional Development, Phoenix, Arizona - 9/14/2013
Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Dynamic and Time-to-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor_Na¥ve Myelofibrosis Patients Treated with Momelo...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Proposal of an endpoint for a phase III clinical study of essential thrombocythemia: Balancing between short term effects and long term benefits.
2019 ASCO Annual Meeting - 6/1/2019
As If Myeloproliferative Neoplasms Weren't Already Challenging Enough
60th American Society of Hematology Annual Meeting - 12/2/2018
Social Media for the Hematologist: Today and in the Future
60th American Society of Hematology Annual Meeting - 12/2/2018
As If Myeloproliferative Neoplasms Weren't Already Challenging Enough
60th American Society of Hematology Annual Meeting - 12/1/2018
Social Media for the Hematologist: Today and in the Future
60th American Society of Hematology Annual Meeting - 12/1/2018
Real-World Risk Assessment and Treatment of Patients with Myelofibrosis at Community Oncology Practices in the United StatesClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intole...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Characteristics Associated with Hydroxyurea Treatment Change in Patients with Polycythemia Vera: An Analysis from the Reveal Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Correlation between MPN-SAF TSS and EORTC QLQ-C30 Scores in Patients with PV: Data from the Reveal StudyClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A phase 2, multicenter, open-label study of the safety and efficacy of luspatercept in subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis and ane...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Authored Content

Watch: Momelotinib for Myelofibrosis — Top 10 Takeaways Physicians Should Know Post-FDA approvalSeptember 2023
ASH 2020: An Explosion of Options for MPNs ForthcomingDecember 2020

Press Mentions

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in MyelofibrosisOctober 31st, 2024
New Insights Emerge on Treatment Outcomes for Accelerated or Blast-Phase Myeloproliferative NeoplasmsOctober 4th, 2024
Wake Forest University School of Medicine Receives $2.7 Million Grant from National Cancer Institute to Study Lung Cancer DisparitiesApril 19th, 2023
Join now to see all

Grant Support

Apoptosis In Myelofibrosis With Myeloid MetaplasiaNational Cancer Institute2004–2006
Apoptosis In Myelofibrosis With Myeloid MetaplasiaNational Cancer Institute2002–2003
Truncated C-Erbb Receptors In Ovarian CarcinomasNational Cancer Institute1992